We research, we develop, we bring true innovations to the marketplace. Is that also your goal? Do you also want to sustainably improve the lives of our patients?
Are you an innovative researcher, an unconventional thinker, a strategist, a visionary, a creative thinker, a pragmatist, or a go-getter? In short, are you a person who will rise to the challenge and make a difference?
Then we look forward to telling you more about Grünenthal—about us, what makes us tick, and how we can reach our goals together - every day, worldwide.
Aachen, Germany, 22 January 2019 – Grünenthal announced today that Fabian Raschke has been appointed Chief Financial Officer (CFO) and Member of the Corporate Executive Board. He will assume leadership of Grünenthal’s Finance and IT organisation on 1 February 2019. Fabian currently leads Grünenthal’s Group Controlling and manages over 150 employees, including Finance staff in the affiliates.
Aachen, Germany / Morristown, New Jersey, USA, 14 November, 2018 – Grünenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza® (8 % capsaicin) for Grünenthal in the US. Grünenthal had only recently acquired the remaining global rights, including the US rights, for the product from Acorda Therapeutics